Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line

Recently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after one of its weakest years in recent memory.